Company Profile
Milestone Pharmaceuticals Inc. Stock Price, News & Analysis
- Ticker:
- MIST
- Exchange:
- NASDAQ
- Sector:
- Biotechnology
- Location:
- Headquartered in the United States and listed on NASDAQ, Milestone Pharmaceuticals is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Stock performance
1.30 USD (-0.76%)
Close
Last updated: June 23, 2026 at 00:00
161.85M USD
Market cap
Why the stock is moving
MIST is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Company overview
Business overview
Milestone Pharmaceuticals is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Milestone Pharmaceuticals is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Business Model Characteristics
Milestone Pharmaceuticals follows a pipeline-led model where clinical readouts, filing updates, and program expansion determine how the market underwrites the story.
Position Within the Biotechnology Landscape
Compared with more mature healthcare names, Milestone Pharmaceuticals sits on the development side of the biotech landscape, where catalyst timing can reprice the stock quickly.
Future catalysts
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
Milestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
Source: Milestone Pharmaceuticals Inc.
- 02
Milestone Pharmaceuticals Announces First Quarter 2026 Financial Results and Provides Corporate Update
Source: Milestone Pharmaceuticals Inc.
- 03
Milestone Pharmaceuticals Appoints David Sandoval as General Counsel and Chief Compliance Officer
Source: Milestone Pharmaceuticals Inc.
- 04
Milestone® Pharmaceuticals to Present at the TD Cowen 46th Annual Health Care Conference
Source: Milestone Pharmaceuticals Inc.
- 05
Milestone Pharmaceuticals to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 20, 2026
Source: Milestone Pharmaceuticals Inc.
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Milestone Pharmaceuticals Inc. (MIST)?
Milestone Pharmaceuticals Inc. (MIST) most recently closed at 1.30 USD, a -0.76% move versus the previous session.
What is the market cap of Milestone Pharmaceuticals Inc. (MIST)?
Milestone Pharmaceuticals Inc. currently has a market capitalization of 161.85M USD on BioPharmSignal.
What does Milestone Pharmaceuticals Inc. do?
Milestone Pharmaceuticals is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
On which exchange is MIST stock listed?
Milestone Pharmaceuticals Inc. (MIST) is associated with NASDAQ, Headquartered in the United States and listed on NASDAQ, Milestone Pharmaceuticals is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts., Biotechnology.
What is Milestone?
Milestone Pharmaceuticals is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Which conditions is Milestone Pharmaceuticals Inc. targeting with Milestone?
Milestone Pharmaceuticals is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
What is Pharmaceuticals?
Milestone Pharmaceuticals is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.